What is the 13F Pro Quality Score for SSII?

13F Pro ranks SS Innovations International, Inc. (SSII) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SSII's current score at https://13fpro.ai/research/SSII (free sign-up required for the full ranking).

Where does 13F Pro source SSII data?

All SS Innovations International, Inc. fundamentals and ownership data come directly from SEC EDGAR. SS Innovations International, Inc. files with the SEC under CIK 1676163. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SSII in?

SS Innovations International, Inc. (SSII) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SSII research updated on 13F Pro?

SSII's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

SS Innovations International, Inc.(SSII)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1676163 SSII stock profile & AI dashboard →

13F Pro Quality Score

30.8/100

Rank #2,339 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

94.9/100

Profitability

13.7/100

Balance Sheet

12.6/100

Earnings Quality

30.0/100

Free Cash Flow

8.9/100

Institutional Flow

49.5/100

Revenue Scale

9.0/100

Dilution Risk

9.6/100

SSII Stock Analysis & AI Quality Score

AI stock analysis and institutional research for SS Innovations International, Inc. (SSII), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SSII at 30.8/100 on a 32-signal composite quality model, placing it at rank #2,339 of 2,879 stocks — the bottom half of the AI-ranked universe. SSII scores in the top quartile across revenue growth (94.9). Areas of concern include free cash flow (8.9) and revenue scale (9.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 9.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), SS Innovations International, Inc. reports quarterly revenue of $11.1M, net income of $-3.6M, free cash flow of $-2.4M. Top institutional holders of SSII by reported 13-F value include Hood River Capital Management, UBS Group AG, JNBA Financial Advisors, based on the most recent SEC filings. SSII trades on the Nasdaq exchange and files with the SEC under CIK 1676163. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SSII daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SS Innovations International, Inc. directly from SEC EDGAR. SS Innovations International, Inc.'s 13F Pro composite quality score has ranged between 31 and 32 since 2026, currently 30.8 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about SS Innovations International, Inc.

Quirks, history, and lore behind SSII — the kind of stuff that makes a stock memorable.

1
The Basics
A healthcare technology company headquartered in India, listed on Nasdaq, operating in the surgical robotics space.
2
The Numbers
A small-cap company with revenues still in early-growth territory — this is a pre-profitability story, betting big on a market dominated by a single giant.
3
The History
Founded by a cardiac surgeon who wanted to bring robotic-assisted surgery to markets historically priced out of the technology — particularly emerging economies.
4
The Secret
Its flagship system is designed to be more affordable than incumbent robotic platforms, targeting hospitals in Asia, Africa, and beyond that can't write a $2 million check to the competition.
5
The Lore
The founder performed thousands of open-heart surgeries before pivoting to build the robot he wished he'd had — making this one of the few medtech companies literally built by its own end user.
6
The Giveaway
Its SSi Mantra surgical robot is India's answer to the da Vinci — a made-in-India robotic surgery platform from a company whose ticker literally spells out its founder's initials.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$11.1M

Net Income

Q1 2026

$-3.6M

Free Cash Flow

Q1 2026

$-2.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$42.5MFY 2025

FY19 —FY20 —FY21 —FY25 $42.5M

Net Income

-717.0% YoY

$-12.1MFY 2025

FY19 $-3.4MFY20 $-1.1MFY21 $-1.5MFY25 $-12.1M

Operating Income

$-8.2MFY 2025

FY19 —FY20 —FY21 —FY25 $-8.2M

EPS (Diluted)

-259.3% YoY

$-0.06FY 2025

FY19 $-0.05FY20 $-0.02FY21 $-0.02FY25 $-0.06

Total Assets

+17218.0% YoY

$74.2MFY 2025

FY19 $132.5KFY20 $317.9KFY21 $428.6KFY25 $74.2M

Op. Cash Flow

-5007.8% YoY

$-18.5MFY 2025

FY19 $-424.1KFY20 $-90.5KFY21 $-363.0KFY25 $-18.5M

Metric	FY 2025	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	$42.5M	—	—	—	—	—
Net Income	$-12.1M -717.0%	$-1.5M -32.0%	$-1.1M +66.8%	$-3.4M -252.6%	$-960.3K +7.5%	$-1.0M
Operating Income	$-8.2M	—	—	—	—	—
EPS (Diluted)	$-0.06 -259.3%	$-0.02 +0.0%	$-0.02 +68.7%	$-0.05	—	—
Total Assets	$74.2M +17218.0%	$428.6K +34.8%	$317.9K +139.9%	$132.5K -8.9%	$145.4K -71.5%	$510.0K
Operating Cash Flow	$-18.5M -5007.8%	$-363.0K -301.0%	$-90.5K +78.7%	$-424.1K +4.3%	$-443.3K +0.8%	$-446.9K

AI Insight: SSII Financial Trends

Revenue growth stalled in Q1 2026 after three consecutive quarters of acceleration, while operating losses widened despite prior-quarter improvements.

• Revenue surged from $5M in Q1 2025 to $15M in Q4 2025, then declined 27% to $11M in Q1 2026.

• Operating income improved from -$6M in Q1 2025 to -$1M in Q4 2025, but deteriorated to -$4M in Q1 2026.

• Equity surged to $55M in Q1 2026, up from $38M in Q4 2025, indicating capital infusion despite ongoing losses.

⚠ Operating cash flow negative every quarter; Q1 2026 shows -$2M despite revenue of $11M — cash burn persists.

⚠ Q1 2026 revenue reversal breaks 3-quarter growth streak; trajectory unclear heading into Q2 2026.

AI Insight: SSII Ratio Trends

SSII remains deeply unprofitable across all efficiency metrics, with operating margin swinging wildly from +3.0% in Q2 2025 back to -32.8% in Q1 2026.

• OpMargin deteriorated 27.8pp from Q2 2025 (+3.0%) to Q1 2026 (-32.8%), erasing the only profitable quarter in the dataset.

• NPM has remained deeply negative across all nine periods, ranging from -110.9% to -2.6%, indicating persistent core profitability issues.

• ROE, ROA, and ROIC all remain negative; Q1 2026 ROE of -26.3% and ROIC of -26.7% show no sustainable return generation.

⚠ Q2 2025 brief return to operating profitability (+3.0%) was followed by renewed losses; pattern suggests operational instability or one-off gains.

⚠ Leverage minimal (D/E 0.04 when reported); balance sheet strength offers limited cushion for continued operating losses.

Get alerted when SSII's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SS Innovations International, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SSII

Hood River Capital Management LLC
$4.2M833,333 sh
UBS Group AG
$777.7K155,541 sh
JNBA Financial Advisors
$584.7K116,937 sh
Eversept Partners, LP
$550.8K110,157 sh
Inspire Investing, LLC
$523.1K104,624 sh
AlphaCentric Advisors LLC
$250.0K50,000 sh
Forum Financial Management, LP
$192.3K38,469 sh
GEODE CAPITAL MANAGEMENT, LLC
$181.4K36,276 sh
AlTi Global, Inc.
$102.8K20,555 sh
Mariner, LLC
$93.3K18,657 sh

Fund	Value	Shares
Hood River Capital Management LLC	$4.2M	833,333
UBS Group AG	$777.7K	155,541
JNBA Financial Advisors	$584.7K	116,937
Eversept Partners, LP	$550.8K	110,157
Inspire Investing, LLC	$523.1K	104,624
AlphaCentric Advisors LLC	$250.0K	50,000
Forum Financial Management, LP	$192.3K	38,469
GEODE CAPITAL MANAGEMENT, LLC	$181.4K	36,276
AlTi Global, Inc.	$102.8K	20,555
Mariner, LLC	$93.3K	18,657

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SSII on your watchlist

Track score changes the day SS Innovations International, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SSII a good stock to buy?

13F Pro's AI-powered analysis of SS Innovations International, Inc. (SSII) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SSII are available on the SSII stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SSII?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SSII. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SS Innovations International, Inc.'s investment landscape.